ESR1 and breast cancer: The main aim of our research was to verify whether the combination of TAM, a selective estrogen receptor modulator, recommended for the treatment of positive estrogen receptor (ER+) breast cancer, to the currently employed conservative CKD treatment, here represented by RAAS blockade and immunosuppression, would promote additional anti-inflammatory and/or antifibrotic beneficial effects, when compared to the respective monotherapies.